Bayer AG announced positive results from the Phase 3 ARANOTE trial for darolutamide, demonstrating a significant reduction in the risk of disease progression or death in patients with metastatic hormone-sensitive prostate cancer (mHSPC). These findings could lead to expanded use of darolutamide for mHSPC patients.